- Home
- LYRA vs IBIO Comparison
LYRA vs IBIO Comparison
Compare LYRA & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- IBIO
- Stock Information
- Founded
- LYRA 2005
- IBIO 2008
- Country
- LYRA United States
- IBIO United States
- Employees
- LYRA N/A
- IBIO N/A
- Industry
- LYRA Medical/Dental Instruments
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- LYRA Health Care
- IBIO Health Care
- Exchange
- LYRA Nasdaq
- IBIO Nasdaq
- Market Cap
- LYRA 11.3M
- IBIO 11.9M
- IPO Year
- LYRA 2020
- IBIO N/A
- Fundamental
- Price
- LYRA $6.41
- IBIO $0.84
- Analyst Decision
- LYRA Hold
- IBIO Strong Buy
- Analyst Count
- LYRA 1
- IBIO 2
- Target Price
- LYRA $16.00
- IBIO $5.50
- AVG Volume (30 Days)
- LYRA 14.8K
- IBIO 1.9M
- Earning Date
- LYRA 11-11-2025
- IBIO 11-11-2025
- Dividend Yield
- LYRA N/A
- IBIO N/A
- EPS Growth
- LYRA N/A
- IBIO N/A
- EPS
- LYRA N/A
- IBIO N/A
- Revenue
- LYRA $770,000.00
- IBIO $400,000.00
- Revenue This Year
- LYRA N/A
- IBIO N/A
- Revenue Next Year
- LYRA $123.46
- IBIO N/A
- P/E Ratio
- LYRA N/A
- IBIO N/A
- Revenue Growth
- LYRA N/A
- IBIO 77.78
- 52 Week Low
- LYRA $3.81
- IBIO $0.56
- 52 Week High
- LYRA $37.50
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- LYRA 38.58
- IBIO 52.86
- Support Level
- LYRA $6.15
- IBIO $0.77
- Resistance Level
- LYRA $6.72
- IBIO $0.97
- Average True Range (ATR)
- LYRA 0.38
- IBIO 0.06
- MACD
- LYRA -0.01
- IBIO -0.00
- Stochastic Oscillator
- LYRA 25.85
- IBIO 36.45
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.